Supernus Pharmaceuticals (SUPN) EBITDA Margin (2011 - 2026)
Supernus Pharmaceuticals (SUPN) recorded EBITDA Margin of -14.71% in Q2 2026, down 34.95 percentage points from 20.25% a year earlier.
Powered by 
Analysis
Supernus Pharmaceuticals (SUPN) EBITDA Margin (2011 - 2026) Analysis & Trends
On a TTM basis, Supernus Pharmaceuticals' EBITDA Margin came in at -1.66% as of Jun 30, 2026, down 23.43 percentage points year-over-year; for FY2025, it was 4.07%, down 20.42 percentage points from FY2024.
- Annual EBITDA Margin has a five-year change of -32.79 percentage points (FY2020 to FY2025).
- Across earlier years, EBITDA Margin came in at 24.49% in FY2024 (+11.39 pp), 13.10% in FY2023 (-6.63 pp), 19.73% in FY2022 (-0.73 pp) and 20.46% in FY2021 (-16.40 pp).
- Quarterly EBITDA Margin has ranged from -18.44% in Q3 2025 to 34.69% in Q3 2024 over the past five years.
- On a year-over-year basis, EBITDA Margin rose in two of the last seven quarters, with an average year-over-year change of -12.35 percentage points.
- Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 23.40 percentage points in Q2 2024, against a drop of 53.13 percentage points in Q3 2025 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Supernus Pharmaceuticals | 2.59 Bn | 1.25 Bn | 185.39 Mn | -14.71% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.71% |
| Dec 31, 2025 | 9.96% |
| Sep 30, 2025 | -18.44% |
| Jun 30, 2025 | 20.25% |
| Mar 31, 2025 | 6.76% |
| Dec 31, 2024 | 23.11% |
| Sep 30, 2024 | 34.69% |
| Jun 30, 2024 | 25.72% |
| Mar 31, 2024 | 12.25% |
| Dec 31, 2023 | 12.59% |
| Sep 30, 2023 | 19.49% |
| Jun 30, 2023 | 2.31% |
| Mar 31, 2023 | 16.76% |
| Dec 31, 2022 | 32.98% |
| Sep 30, 2022 | 11.42% |
| Jun 30, 2022 | 19.35% |
| Mar 31, 2022 | 15.30% |
| Dec 31, 2021 | 11.82% |
| Sep 30, 2021 | 26.46% |
| Jun 30, 2021 | 28.82% |
API Access
Supernus Pharmaceuticals EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SUPN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "SUPN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SUPN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();